Pharmafile Logo
Pharmafocus logo
Advanced Search

Oncology

Showing 15 posts of 302 posts found.

Lung cancer cells

Graphene-based biosensor to support new lung cancer screening test

August 18, 2025
Business Services, Research and Development Ease Healthcare, Hawkeye Bio, HydroGraph, Oncology, lung cancer

HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and Ease Healthcare to support the …

News
money-2180330_960_720

Anocca secures £32m to advance pancreatic cancer trial

August 18, 2025
Research and Development Anocca, Oncology, Pancreatic cancer, research funding

Swedish biopharma Anocca has raised approximately £32m (SEK 440m) to support the early-stage clinical development of VIDAR-1, its lead TCR-T …

News
bonecells

OS Therapies advances regulatory pathway for bone cancer therapy

August 11, 2025
Medical Communications, Research and Development European Medicines Agency’, Medicines and Healthcare products Regulatory Agency, OS Therapies, Oncology, Orthopaedics, US Food and Drug Administration’, bone cancer, osteosarcoma

OS Therapies has announced significant progress in its regulatory strategy for OST-HER2, its lead immunotherapy candidate for preventing or delaying …

News

ARTBIO expands board and establishes technical advisory board

August 11, 2025
Medical Communications, Research and Development ARTBIO, Corporate, Oncology, advisory board, radiopharmaceuticals

ARTBIO, a radiopharma company developing radioligand therapies (RLTs), has appointed four new members to its board of directors and formed …

Appointment
drug-trials

Faron reports increased remission rate in trial for myelodysplastic syndrome candidate

August 7, 2025
Medical Communications, Research and Development Faron Pharmaceuticals, Oncology, US Food and Drug Administration, acute myeloid leukemia, myelodysplastic syndrome

Faron Pharmaceuticals has reported a rise in complete remission (CR) rates among patients with frontline high-risk myelodysplastic syndrome (HR-MDS) in …

News
blood-1813410_960_720

FDA grants orphan drug designation to relapsed or refractory multiple myeloma candidate

August 6, 2025
Medical Communications, Research and Development Oncology, Sanofi, US Food and Drug Administration, myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, Sanofi’s investigational monoclonal antibody developed for …

News

Ryvu Therapeutics publishes research revealing potential drug combination for colorectal cancer

August 1, 2025
Medical Communications, Research and Development Oncology, Ryvu Therapeutics, colorectal cancer

Ryvu Therapeutics has published new findings from its ONCO Prime target discovery platform in Scientific Reports. The study reveals a …

News

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer

July 30, 2025
Medical Communications, Research and Development AstraZeneca, NHS, National Institute for Health and Care Excellence, Oncology, dual immunotherapy, hepatocellular carcinoma, liver cancer

AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its dual immunotherapy …

News
europe-1395916_640

Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment

July 30, 2025
Medical Communications, Research and Development European Commission, Oncology, Sanofi, Sarclisa, european union, multiple myeloma

Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and …

News

ViroCell Biologics and AvenCell Therapeutics partner to accelerate allogeneic CAR-T therapy development

July 29, 2025
Contract Manufacturing, Manufacturing Services, Mergers and Acquisitions, Research and Development AvenCell Therapeutics, CAR-T therapy, Contract Development Manufacturing Organisation, Good Manufacturing Practice, Immunology, Oncology, ViroCell Biologics, autoimmune diseases, blood cancer

ViroCell Biologics has announced a new manufacturing collaboration with AvenCell Therapeutics to produce a high-yield retroviral vector supporting the clinical …

News

Jazz Pharmaceuticals appoints Renée Galá as CEO to lead next phase of growth

July 16, 2025
Research and Development CEO, Corporate, Neurology, Oncology, jazz pharmaceuticals, neurology, neuroscience

Jazz Pharmaceuticals has named Renée Galá as its next chief executive officer (CEO), effective 11 August 2025. Galá, currently president …

Appointment
money_pills_2

VIVES Partners contributes to €84m funding for radiopharma company, Nuclidium

July 14, 2025
Medical Communications, Research and Development Nuclidium, Oncology, VIVES Funds, VIVES Partners, radiopharmaceuticals, radiotheranostics

VIVES Partners, the managing company of VIVES Funds, has announced that it will contribute to an €84m Series B financing …

News

BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design

July 11, 2025
Research and Development BioLabs, BioMed X, Cancer, Oncology, Servier, XSeed Labs, antibody therapy, oncology

BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, located at the Spartners incubator …

News

Eppendorf Award for Young European Investigators 2025 awarded to neuroscientist Varun Venkataramani

July 10, 2025
Medical Communications, Medical/ Scientific Writing, Research and Development Neurology, Oncology

Varun Venkataramani, of Heidelberg University Hospital, Germany, has been awarded the 2025 Eppendorf Award for Young European Investigators for his …

News
brain_scan_small

Duke Street Bio receives FDA fast track designation for brain metastases treatment

July 8, 2025
Medical Communications, Research and Development Duke Street Bio, Oncology, US Food and Drug Administration, brain metastases, breast cancer, fast track designation

Duke Street Bio, a biotech company based in London, UK, has announced that the US Food and Drug Administration (FDA) …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026